Acurx Pharmaceuticals (ACXP) Other financing activities (2020 - 2024)
Acurx Pharmaceuticals' (ACXP) quarterly Other financing activities came in at $210199.0 in Q1 2024, down 53.89% on a QoQ basis from $455874.0 in Q3 2020.
Acurx Pharmaceuticals (ACXP) Other financing activities (2020 - 2024) Analysis & Trends
Acurx Pharmaceuticals (ACXP) has 2 years of Other financing activities data on file, last reported at $210199.0 in Q1 2024.
- Quarterly Other financing activities changed N/A year-over-year to $210199.0 in Q1 2024, while the trailing twelve-month figure through Dec 2024 was $210199.0 (changed N/A YoY) and the FY2025 annual result came in at $1.4 million, up 547.26% from the prior year.
- Other financing activities declined to $210199.0 in Q1 2024, from $455874.0 in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $455874.0 in Q3 2020 to a low of $210199.0 in Q1 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Acurx Pharmaceuticals | 6.18 Mn | 6.18 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 210,199.00 |
| Mar 31, 2024 | 210,199.00 |
| Sep 30, 2020 | 455,874.00 |
| Sep 30, 2020 | 455,874.00 |